Openbookopenbook
Equity
Regnum Corp(RGMP)
USD --+0.00%
Reward38Moderate
Risk70High
📊75%Data
Revenue growing 125% YoY
RGMP
+0.0 · +0.00%
USD · PINK
Regnum Corp | Communication Services
Capital Destroyer
Market Cap:2295
ℹ️
Reward Rating
38
Moderate
Bottom 5% (model universe)
75% data coverage
ℹ️
Risk Rating
70
High
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on RGMP to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Regnum Corp?

develops and commercializes therapeutics that treat rare and infectious diseases.

RGMP · Verdict

Limited reward · elevated risk

RGMP's standout is volatility; balance sheet and profitability weigh on the picture.

Based on 88% data coverage

RGMP · Verdict

What’s working & what to watch

Strengths 1

  • Volatility75/100

    Above average

Watchouts 4

  • Balance sheet6/100

    Current ratio 0.43

  • Profitability10/100

    0% return on equity

  • Cash flow25/100

    Below average

  • Growth41/100

    Earnings +177.9% CAGR

Model-based scoring. For information only — not financial advice.

What is Regnum Corp?

develops and commercializes therapeutics that treat rare and infectious diseases. It develops Leronlimab (PRO 140), a monoclonal antibody C"C chemokine receptor type 5 antagonist, that is designed to prevent human immunodeficiency virus from entering human cells. The company is listed on the PINK in USA, operating in the Communication Services sector, with a market capitalisation of 2.29K.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Moderate volatility with meaningful macro and earnings sensitivity.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (38)

The scoring profile indicates weak reward characteristics across most factors, including valuation and momentum. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.

For informational purposes only. Not financial advice.

Company Information
SectorCommunication Services
Market Cap2.29K
P/E RatioN/A
Dividend YieldN/A
52 Week High0.0001
52 Week Low0.0001
Last AnnualDecember
IPO DateN/A
IncorporatedUSA
Shares Outstanding23M
No. of Employees1
IndustryEntertainment
ExchangePINK
Beta-0.468
CurrencyUSD
Websitewww.regnumcorp.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.